BOSTON--(BUSINESS WIRE)--Sept. 18, 2006--Point Therapeutics, Inc. (NASDAQ: POTP) announced today that talabostat's Phase 2 non-small cell lung cancer (NSCLC) program and dual mechanism of action was presented on Saturday, September 16, 2006 at the 14th International Conference on Gene Therapy of Cancer in Dallas, Texas. Dr. Casey Cunningham, an oncologist at Mary Crowley Research Center in Dallas, Texas and a member of Point's Clinical Advisory Board, presented a summary of the Phase 2 NSCLC trial results. Dr. Barry Jones, Point's Senior Vice President and Chief Scientific Officer, presented an overview of talabostat's novel dual mechanism of action, emphasizing the pathway of immune stimulation.
